⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027522 | 0.87 | — | — | |
| SCHEMBL4800652 | 0.87 | FFAR3 (0.31) | — | |
| SCHEMBL28743535 | 0.80 | CYP2C19 (0.32) | — | |
| SCHEMBL3810212 | 0.75 | — | — | |
| SCHEMBL1082425 | 0.74 | — | — | |
| SCHEMBL30114587 | 0.73 | PIK3CA (0.37) | — | |
| SCHEMBL9358435 | 0.72 | — | — | |
| SCHEMBL3310180 | 0.72 | — | — | |
| SCHEMBL8190823 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL25356046 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448946-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | Novartis AG (CH) | 2012-05-09 | — | — | EP | claimed |
| EP-2331537-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-06-15 | — | — | EP | claimed |
| WO-2011000855-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | claimed |
| EP-2875050-A1 | COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K | Novartis AG (CH) | 2015-05-27 | — | — | EP | disclosed |
| US-20140275089-A1 | 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8710085-B2 | Pyrrolidine-1,2-dicarboxamide derivatives | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| WO-2014015280-A1 | COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K | NOVARTIS PHARMA AG (CH) | 2014-01-23 | — | — | WO | disclosed |
| EP-2331537-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |